A Translational Study of Orelabrutinib Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) as First-Line Treatment for Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged ≥ 18 years;
• Pathologically confirmed diffuse large B-cell lymphoma (DLBCL) by tumor tissue, with at least one measurable lesion, including DLBCL, not otherwise specified (GCB and non-GCB subtypes), DLBCL with MYC and BCL-2 rearrangements, and high-grade B-cell lymphoma;
• No prior receipt of other anti-tumor treatments;
• ECOG performance status 0-2;
• IPI score 2-5, and patients with stage III-IV disease;
• Life expectancy ≥ 6 months;
• Voluntarily sign a written informed consent form.
Locations
Other Locations
China
the First Affiliated Hospital of Xiamen University
RECRUITING
Xiamen
the First Affiliated Hospital of Xiamen University
RECRUITING
Xiamen
Contact Information
Primary
Bing Xu, PhD，MD
xubingzhangjian@126.com
18750918842
Time Frame
Start Date: 2026-08-30
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 30
Treatments
Experimental: Orelabrutinib Plus Pola-R-CHP Regimen
Orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP)
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital of Xiamen University